ProteoThera Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Out of Business

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Out of Business

ProteoThera General Information

Description

Developer of a drug targeting technology designed to improve clinical efficacy. The company's technology can generate new pharmacokinetic profiles for therapies, transforming systemically delivered drugs into locally or subcutaneous delivered proteins, peptides and small molecules, enabling medical practitioners to improve the safety profile by reducing or eliminating side effects associated with whole-body systemic exposure.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 2227 Washington Street
  • Suite 203, Two Newton Executive Park
  • Newton, MA 02462
  • United States
+1 (617)
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2227 Washington Street
  • Suite 203, Two Newton Executive Park
  • Newton, MA 02462
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ProteoThera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 30-Oct-2020 Completed Out of Business
3. Early Stage VC 22-Dec-2015 Cancelled Clinical Trials - Phase 1
2. Early Stage VC 01-Aug-2014 $3.1M $3.1M Completed Startup
1. Grant 01-Jan-2012 $1.5M Completed Startup
To view ProteoThera’s complete valuation and funding history, request access »

ProteoThera Patents

ProteoThera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170328886-A1 Systems and methods for determining therapeutic uptake and dosing Inactive 13-May-2016
EP-3373954-A2 Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography Inactive 10-Nov-2015
EP-3373954-A4 Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography Inactive 10-Nov-2015
US-20190016754-A1 Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography Inactive 10-Nov-2015
WO-2017083491-A2 Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography Inactive 10-Nov-2015 C07K1/22
To view ProteoThera’s complete patent history, request access »

ProteoThera Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ProteoThera FAQs

  • When was ProteoThera founded?

    ProteoThera was founded in 2012.

  • Where is ProteoThera headquartered?

    ProteoThera is headquartered in Newton, MA.

  • What is the size of ProteoThera?

    ProteoThera has 7 total employees.

  • What industry is ProteoThera in?

    ProteoThera’s primary industry is Drug Delivery.

  • Is ProteoThera a private or public company?

    ProteoThera is a Private company.

  • What is ProteoThera’s current revenue?

    The current revenue for ProteoThera is .

  • How much funding has ProteoThera raised over time?

    ProteoThera has raised $3.1M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process